More than 6,000 lawsuits have been filed in the federal multidistrict litigation (MDL) established in the Northern District of Illinois. The plaintiffs have alleged injuries and damages that resulted from their use of Low T medications that were unsafe because of heart attack, stroke and blood clot risks. The majority of these lawsuits name AbbVie as a defendant. AbbVie produces the popular “Androgel” Low T medication. The claims against AbbVie allege that the company knew of that the drug increased the risks of heart attacks, strokes and blood clots among its users, yet failed to warn the users about those risks.
Judge Matthew Kennelley, who is assigned to these cases has selected eight of them for trial. Four of the eight cases will involve a plaintiff who took AndroGel and then suffered a heart attack or stroke, and the other four will involve a plaintiff who took AndroGel and suffered a blood clot, such as a pulmonary embolism (PE) or deep vein thrombosis (DVT). The first trial is scheduled to begin in 2017. The outcome of these trials could likely influence the future litigation in the Low T MDL.
If you or a loved one has experienced a cardiac event such as a heart attack or stroke or a blood clot such as a DVT or PE after using a Low T medication, you may be entitled to compensation. Contact the Low-T lawyers at the Levensten Law Firm at www.levenstenlawfirm.com, www.androgellawyers.com or 215-545-5600 for a free consultation.